Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications

Journal of Peptide Science

Volumn 17, Issue 2, 2011, Pages 154-162

  Accardo, Antonella ^a   Morisco, Anna ^a   Gianolio, Eliana ^b   Tesauro, Diego ^a   Mangiapia, Gaetano ^a   Radulescu, Aurel ^c   Brandt, Astrid ^d   Morelli, Giancarlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Jülich Center for Neutron Science JCNS   (Germany)

^d HAHN MEITNER INSTITUT   (Germany)

Author keywords

Amphiphilic gadolinium complexes; MRI contrast agents; Octreotide peptide; Small angle neutron scattering; Supramolecular aggregates

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMPHOPHILE; CONTRAST MEDIUM; CYCLOPEPTIDE; ETHYLENE DERIVATIVE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIC ACID; GLUTAMINE; LYSINE; MONOMER; NANOPARTICLE; OCTREOTIDE; PENTETIC ACID; PENTETIC ACID DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SURFACTANT; TRYPTOPHAN; WATER;

AMINO TERMINAL SEQUENCE; ARTICLE; BILAYER MEMBRANE; COMPLEX FORMATION; DRUG BINDING; DRUG RECEPTOR BINDING; FLUORESCENCE; HYDROPHOBICITY; MACROMOLECULE; MICELLE; NEUTRON SCATTERING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN AGGREGATION; STRUCTURE ANALYSIS; SURFACE PROPERTY; THICKNESS;

CONTRAST MEDIA; GADOLINIUM; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; OCTREOTIDE;

EID: 78651440633     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1308     Document Type: Article

References (47)

1. Berthold M, Bartfai T. Modes of peptide binding in G Protein-Coupled Receptors. Neurochem. Res. 1997; 22: 1023-1031.
2. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 2003; 24: 389-427.
3. Lamberts SWJ. Octreotide: The Next Decade. Bioscientifica: UK, Bristol, UK, 1999.
4. Bauer W, Briner U, Doepfner W. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982; 31: 1133-1140.
5. Veber DF, Freidinger RM, Schwenk-Perlow D, Paleveda WJ Jr, Holly FW, Strachan RG, Nurr RF, Arison BH, Homnick C, Randall WC, Glitzer MS, Saperstein R, Hirschmann R. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981; 292: 55-58.
6. Patel CY. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999; 20: 157-198.
7. Hofland LJ. Internalization of [DOTA, 125I-Tyr3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc. Assoc. Am. Physicians 1999; 111: 63-69.
8. Huang CM, Wu YT, Chen ST. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol. 2000; 7: 453-461.
9. Mier W, Eritja R, Ashour M, Haberkorn U, Eisenhut M. Peptide-PNA conjugates targeted transport of antisense therapeutics into tumours. Angew. Chem. Int. Ed. 2003; 42: 1968-1971.
10. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 1991; 12: 450-482.
11. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. In Nuclear Medicine Annual, Freeman LM (ed.). Lippincott-Raven: New York, 1995; 1-50.
12. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001; 28: 836-846, Erratum in: Eur. J. Nucl. Med. 2001; 28: 1433.
13. Froidevaux S, Eberle AN. Somatostatin analogues and radiopeptides in cancer therapy. Biopolymers (Pept. Sci.) 2002; 66: 161-183.
14. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002; 2: 750-763.
15. Wu H, Chang D-K. Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J. Oncol. 2010; ASAP DOI 10.1155/2010/723798.
16. van Tilborg GAF, Mulder WJM, Deckers N, Storm G, Reutelingsperger CPM, Strijkers GJ, Nicolay K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem. 2006; 17: 741-749.
17. Mulder WJM, Strijkers GJ, van Tilborg GAF, Cormode DP, Fayad ZA, Nicolay K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc. Chem. Res. 2009; 42: 904-914.
18. Bull SR, Guler MO, Bras RE, Maede TJ, Stupp SI. Self-assembled peptide amphiphile nanofibers conjugated to MRI contrast agents. Nano Lett. 2005; 5: 1-4.
19. Kluza E, van der Schaft DWJ, Hautvast PAI, Mulder WJM, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K. Synergistic targeting of αvβ3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2010; 10: 52-58.
20. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005; 5: 161-171.
21. Accardo A, Tesauro D, Roscigno P, Gianolio E, Paduano L, D'Errico G, Pedone C, Morelli G. Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. J. Am. Chem. Soc. 2004; 126: 3097-3107.
22. Accardo A, Tesauro D, Morelli G, Gianolio E, Aime S, Vaccaro M, Mangiapia G, Paduano L, Schillén K. High-relaxivity supramolecular aggregates containing peptides and Gd complexes as contrast agents. J. Biol. Inorg. Chem. 2007; 12: 267-276.
23. Vaccaro M, Mangiapia G, Paduano L, Gianolio E, Accardo A, Tesauro D, Morelli G. Structural and relaxometric characterization peptide aggregates containing gadolinium complexes as potential selective contrast agents in MRI. ChemPhysChem 2007; 8: 2526-2538.
24. Tesauro D, Accardo A, Gianolio E, Paduano L, Teixeira J, Schillen K, Aime S, Morelli G. Peptide derivatized lamellar aggregates as target-specific MRI contrast agents. ChemBioChem 2007; 8: 950-955.
25. Accardo A, Mansi R, Morisco A, Mangiapia G, Paduano L, Tesauro D, Radulescu A, Aurilio M, Aloj L, Arra C, Morelli G. Peptide modified nanocarriers for selective targeting of bombesin receptors. Mol. Biosyst. 2010; 6: 878-887.
26. Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G. Micelles derivatized with octreotide as potential target-selective contrast agents in MRI. J. Pept. Sci. 2009; 15: 242-250.
27. Anelli PL, Fedeli F, Gazzotti O, Lattuada L, Lux G, Rebasti F. L-glutamic acid and L-lysine as useful building blocks for the preparation of bifunctional DTPA-like ligands. Bioconjug. Chem. 1999; 10: 137-140.
28. Schmitt L, Dietrich C. Synthesis and characterization of chelator-lipids for reversible immobilization of engineered proteins at self-assembled lipid interfaces. J. Am. Chem. Soc. 1994; 116: 8485-8491.
29. Ellmann GL. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 1959; 82: 70-77.
30. Brunisholz G, Randin M. The separation of the rare earths by ethylenediamine-tetraacetic acid (EDTA). IX. A cycle for the separation of the rare earths by fractionation. Helv. Chim. Acta 1959; 42: 1927-1938.
31. Edelhoch H. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 1967; 6: 1948-1954.
32. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995; 4: 2411-2423.
33. Vaccaro M, Accardo A, Tesauro D, Mangiapia G, Löf D, Schillen K, Soederman O, Morelli G, Paduano L. Supramolecular aggregates of amphiphilic gadolinium complexes as blood pool MRI/MRA contrast agents: physicochemical characterization. Langmuir 2006; 22: 6635-6643.
34. Wignall GD, Bates FS. Absolute calibration of small-angle neutron scattering data. J. Appl. Crystallogr. 1987; 20: 28-40.
35. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AJ, Trubetskoy VS, Herron JN, Gentry CA. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1994; 119: 11-20.
36. Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Liu X, Hoffend J, Haberkorn U, Eisenhut M, Mier W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nucl. Med. Biol. 2004; 31: 21-30.
37. Anelli PL, Lattuada L, Lorusso V, Schneider M, Tournier H, Uggeri F. Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents. Magn. Res. Mater. Phys. Biol. Med. 2001; 12: 114-120.
38. Chan WC, White PD. Fmoc Solid Phase Peptide Synthesis. Oxford University Press: New York, 2000.
39. Lackowicz JR. Principles of Fluorescence Spectroscopy. Plenum Press: New York, 1983.
40. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 1999; 99: 2293-2352.
41. Bloembergen N, Morgan LO. Proton relaxation times in paramagnetic solutions. Effects of electron spin relaxation. J. Chem. Phys. 1961; 34: 842-850.
42. Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. J. Am. Chem. Soc. 1982; 104: 4546-4559.
43. Lipari G, Szabo A. Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 2. Analysis of experimental results. J. Am. Chem. Soc. 1982; 104: 4559-4570.
44. Aime S, Botta M, Fasano M, Paoletti S, Terreno E. Relaxometric determination of the exchange rate of the coordinated water protons in a neutral Gd-III chelate. Chem. Eur. J. 1997; 3: 1499-1504.
45. Powell DH, Favre M, Graeppi N, Dhubhghaill OMN, Pubanz D, Merbach AE. Solution kinetic behaviour of lanthanide (III) polyamino carboxylates from O-17 NMR-studies. J. Alloys Compd. 1995; 225: 246-252.
46. Delli Castelli D, Gianolio E, Geninatti Crich S, Terreno E, Aime S. Metal containing nanosized systems for MR-molecular imaging applications. Coord. Chem. Rev. 2008; 252: 2424-2443.
47. Accardo A, Tesauro D, Aloj L, Pedone C, Morelli G. Supramolecular aggregates containing lipophilic Gd(III) complexes as contrast agents in MRI. Coord. Chem. Rev. 2009; 253: 2193-2213.